Showing 2431-2440 of 4063 results for "".
- Sight Sciences Publishes 24-Month SAHARA RCT Results Evaluating TearCare in Dry Eye Diseasehttps://modernod.com/news/sight-sciences-publishes-24-month-sahara-rct-results-evaluating-tearcare-in-dry-eye-disease/2482923/Sight Sciences has published 24-month results from Stage 3 of its landmark SAHARA randomized controlled trial (RCT). The study, published in Optometry and Vision Science, assesses the long-term effi
- Bascom Palmer Eye Institute Tops U.S. News & World Report Rankings for 24th Year in a Rowhttps://modernod.com/news/bascom-palmer-eye-institute-tops-us-news-world-report-rankings-for-24th-year-in-a-row/2482911/For the 24th year, Bascom Palmer Eye Institute has been ranked the No. 1 ophthalmology hospital in the United States, according to the newly released 2025 U.S. News & World Report "Best Hospitals" rankings. This marks the 22nd consecutive year th
- BlueRock Therapeutics Announces First Patient Treated in Phase 1/2a Trial of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-announces-first-patient-treated-in-phase-12a-trial-of-opct-001-for-primary-photoreceptor-diseases/2482877/Bayer and BlueRock Therapeutics announced that the first patient received the investigational therapy in CLARICO, a phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-00
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congresshttps://modernod.com/news/qlaris-bio-to-present-new-clinical-and-preclinical-data-on-qls-111-at-2025-world-glaucoma-congress/2482859/Qlaris Bio announced that new data from studies of its lead investigational compound QLS-111 will be presented at the 2025 World Glaucoma Congress (WGC). This will include an oral presentation on clinical data from the recently completed QC-111-201 “Osprey” and QC-111-203 “
- University of Oklahoma Study Identifies 20 Novel Variants for Inherited Retinal Diseaseshttps://modernod.com/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases/2482824/A new study out of the University of Oklahoma maps 20 new gene mutations contributing to rare inherited retinal diseases (IRDs). Researchers aim to use these findings to improve diagnostic accuracy and identify targets for future
- Nationwide Recall Issued for Multiple OTC Eye Care Productshttps://modernod.com/news/nationwide-recall-issued-for-multiple-otc-eye-care-products/2482809/A voluntary recall for multiple OTC eye care products, including artificial tears and lubricant eye drops, was issued due to serious manufacturing violations identified during an FDA audit. The
- Perfuse Therapeutics Announces Positive Results from Phase 1/2a Trial of PER-001 Intravitreal Implant in Patients with Glaucomahttps://modernod.com/news/perfuse-therapeutics-announces-positive-results-from-phase-12a-trial-of-per-001-intravitreal-implant-in-patients-with-glaucoma/2482794/Perfuse Therapeutics announced positive 24-week results from its completed phase 1/2a trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma. Steven Mansberger, MD, MPH, Chief of Ophthalmology and Director of Gl
- Registration Now Open for Neuro-Optometric Rehabilitation Association (NORA) 2025 Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-nora-2025-conference/2482791/The Neuro-Optometric Rehabilitation Association, International (NORA), which advocates for advancing neurovisual rehabilitation, has opened registration for its 35th Annual Conference, taking place September 18–21, 2025, at the Hilton Denver City Center in Denver, Colorado. N
- Alon Harris, MS, PhD, Named 2025 Recipient of Robert Ritch Award for Innovation and Excellence in Glaucomahttps://modernod.com/news/alon-harris-named-2025-recipient-of-robert-ritch-award-for-innovation-and-excellence-in-glaucoma/2482778/Alon Harris, MS, PhD, FARVO, has been announced as the 2025 recipient of The Glaucoma Foundation’s (TGF) 'Robert Ritch Award for Innovation and Excellence in Glaucoma.' The award, established in 2008 and named after TGF founder Robert Ritch, MD, honor